Compile Data Set for Download or QSAR
Report error Found 134 of affinity data for UniProtKB/TrEMBL: Q96GX5
TargetSerine/threonine-protein kinase greatwall(Human)
Avelos Therapeutics

US Patent
LigandPNGBDBM696045(US20240300936, Example 36 | N4-[1-[1-(difluorometh...)
Affinity DataIC50: 0.646nMAssay Description:Wild-type human MASTL (0.5 nM) was incubated in assay buffer (30 mM HEPES, 100 mM NaCl, 0.5 mM EGTA, 10 mM MgCl2, 0.01% Tween-20, 0.5 mM TCEP, pH 7.5...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetSerine/threonine-protein kinase greatwall(Human)
Avelos Therapeutics

US Patent
LigandPNGBDBM696079(US20240300936, Example 70 | N2-[(2,3-difluoropheny...)
Affinity DataIC50: 0.708nMAssay Description:Wild-type human MASTL (0.5 nM) was incubated in assay buffer (30 mM HEPES, 100 mM NaCl, 0.5 mM EGTA, 10 mM MgCl2, 0.01% Tween-20, 0.5 mM TCEP, pH 7.5...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetSerine/threonine-protein kinase greatwall(Human)
Avelos Therapeutics

US Patent
LigandPNGBDBM696069(US20240300936, Example 60 | N2-[1-[1-(difluorometh...)
Affinity DataIC50: 0.794nMAssay Description:Wild-type human MASTL (0.5 nM) was incubated in assay buffer (30 mM HEPES, 100 mM NaCl, 0.5 mM EGTA, 10 mM MgCl2, 0.01% Tween-20, 0.5 mM TCEP, pH 7.5...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetSerine/threonine-protein kinase greatwall(Human)
Avelos Therapeutics

US Patent
LigandPNGBDBM696132(US20240300936, Example 128)
Affinity DataIC50: 0.851nMAssay Description:Wild-type human MASTL (0.5 nM) was incubated in assay buffer (30 mM HEPES, 100 mM NaCl, 0.5 mM EGTA, 10 mM MgCl2, 0.01% Tween-20, 0.5 mM TCEP, pH 7.5...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetSerine/threonine-protein kinase greatwall(Human)
Avelos Therapeutics

US Patent
LigandPNGBDBM696039(US20240300936, Example 30 | N4-[(2,3-Difluoropheny...)
Affinity DataIC50: 0.933nMAssay Description:Wild-type human MASTL (0.5 nM) was incubated in assay buffer (30 mM HEPES, 100 mM NaCl, 0.5 mM EGTA, 10 mM MgCl2, 0.01% Tween-20, 0.5 mM TCEP, pH 7.5...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetSerine/threonine-protein kinase greatwall(Human)
Avelos Therapeutics

US Patent
LigandPNGBDBM696077(US20240300936, Example 68 | US20240300936, Example...)
Affinity DataIC50: 1.05nMAssay Description:Wild-type human MASTL (0.5 nM) was incubated in assay buffer (30 mM HEPES, 100 mM NaCl, 0.5 mM EGTA, 10 mM MgCl2, 0.01% Tween-20, 0.5 mM TCEP, pH 7.5...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetSerine/threonine-protein kinase greatwall(Human)
Avelos Therapeutics

US Patent
LigandPNGBDBM696021(US20240300936, Example 12 | 6-(1H-indazol-6-yl)-N2...)
Affinity DataIC50: 1.07nMAssay Description:Wild-type human MASTL (0.5 nM) was incubated in assay buffer (30 mM HEPES, 100 mM NaCl, 0.5 mM EGTA, 10 mM MgCl2, 0.01% Tween-20, 0.5 mM TCEP, pH 7.5...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetSerine/threonine-protein kinase greatwall(Human)
Avelos Therapeutics

US Patent
LigandPNGBDBM696031(US20240300936, Example 22 | N2-[1-[1-(Difluorometh...)
Affinity DataIC50: 1.20nMAssay Description:Wild-type human MASTL (0.5 nM) was incubated in assay buffer (30 mM HEPES, 100 mM NaCl, 0.5 mM EGTA, 10 mM MgCl2, 0.01% Tween-20, 0.5 mM TCEP, pH 7.5...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetSerine/threonine-protein kinase greatwall(Human)
Avelos Therapeutics

US Patent
LigandPNGBDBM696027(US20240300936, Example 18 | N2-[2-(2,3-dichlorophe...)
Affinity DataIC50: 1.23nMAssay Description:Wild-type human MASTL (0.5 nM) was incubated in assay buffer (30 mM HEPES, 100 mM NaCl, 0.5 mM EGTA, 10 mM MgCl2, 0.01% Tween-20, 0.5 mM TCEP, pH 7.5...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetSerine/threonine-protein kinase greatwall(Human)
Avelos Therapeutics

US Patent
LigandPNGBDBM696082(US20240300936, Example 73 | N2-[(2-chloro-3-fluoro...)
Affinity DataIC50: 1.26nMAssay Description:Wild-type human MASTL (0.5 nM) was incubated in assay buffer (30 mM HEPES, 100 mM NaCl, 0.5 mM EGTA, 10 mM MgCl2, 0.01% Tween-20, 0.5 mM TCEP, pH 7.5...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetSerine/threonine-protein kinase greatwall(Human)
Avelos Therapeutics

US Patent
LigandPNGBDBM696038(US20240300936, Example 29 | N4-[(2,3-Dichloropheny...)
Affinity DataIC50: 1.29nMAssay Description:Wild-type human MASTL (0.5 nM) was incubated in assay buffer (30 mM HEPES, 100 mM NaCl, 0.5 mM EGTA, 10 mM MgCl2, 0.01% Tween-20, 0.5 mM TCEP, pH 7.5...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetSerine/threonine-protein kinase greatwall(Human)
Avelos Therapeutics

US Patent
LigandPNGBDBM696033(US20240300936, Example 24 | N2-[(2-chloro-3-fluoro...)
Affinity DataIC50: 1.51nMAssay Description:Wild-type human MASTL (0.5 nM) was incubated in assay buffer (30 mM HEPES, 100 mM NaCl, 0.5 mM EGTA, 10 mM MgCl2, 0.01% Tween-20, 0.5 mM TCEP, pH 7.5...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetSerine/threonine-protein kinase greatwall(Human)
Avelos Therapeutics

US Patent
LigandPNGBDBM696037(US20240300936, Example 28 | N2-[1-(2,3-difluorophe...)
Affinity DataIC50: 1.51nMAssay Description:Wild-type human MASTL (0.5 nM) was incubated in assay buffer (30 mM HEPES, 100 mM NaCl, 0.5 mM EGTA, 10 mM MgCl2, 0.01% Tween-20, 0.5 mM TCEP, pH 7.5...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetSerine/threonine-protein kinase greatwall(Human)
Avelos Therapeutics

US Patent
LigandPNGBDBM696040(US20240300936, Example 31 | N4-[2-(2,3-Dichlorophe...)
Affinity DataIC50: 1.51nMAssay Description:Wild-type human MASTL (0.5 nM) was incubated in assay buffer (30 mM HEPES, 100 mM NaCl, 0.5 mM EGTA, 10 mM MgCl2, 0.01% Tween-20, 0.5 mM TCEP, pH 7.5...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetSerine/threonine-protein kinase greatwall(Human)
Avelos Therapeutics

US Patent
LigandPNGBDBM696097(US20240300936, Example 88 | N2-[(2,3-Difluoro-4-me...)
Affinity DataIC50: 1.62nMAssay Description:Wild-type human MASTL (0.5 nM) was incubated in assay buffer (30 mM HEPES, 100 mM NaCl, 0.5 mM EGTA, 10 mM MgCl2, 0.01% Tween-20, 0.5 mM TCEP, pH 7.5...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetSerine/threonine-protein kinase greatwall(Human)
Avelos Therapeutics

US Patent
LigandPNGBDBM696013(US20240300936, Example 4 | 6-(1H-indazol-6-yl)-N2-...)
Affinity DataIC50: 1.95nMAssay Description:Wild-type human MASTL (0.5 nM) was incubated in assay buffer (30 mM HEPES, 100 mM NaCl, 0.5 mM EGTA, 10 mM MgCl2, 0.01% Tween-20, 0.5 mM TCEP, pH 7.5...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetSerine/threonine-protein kinase greatwall(Human)
Avelos Therapeutics

US Patent
LigandPNGBDBM696046(US20240300936, Example 37 | N4-[1-[1-(difluorometh...)
Affinity DataIC50: 1.95nMAssay Description:Wild-type human MASTL (0.5 nM) was incubated in assay buffer (30 mM HEPES, 100 mM NaCl, 0.5 mM EGTA, 10 mM MgCl2, 0.01% Tween-20, 0.5 mM TCEP, pH 7.5...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetSerine/threonine-protein kinase greatwall(Human)
Avelos Therapeutics

US Patent
LigandPNGBDBM696113(US20240300936, Example 104 | N2-[1-[1-(difluoromet...)
Affinity DataIC50: 1.95nMAssay Description:Wild-type human MASTL (0.5 nM) was incubated in assay buffer (30 mM HEPES, 100 mM NaCl, 0.5 mM EGTA, 10 mM MgCl2, 0.01% Tween-20, 0.5 mM TCEP, pH 7.5...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetSerine/threonine-protein kinase greatwall(Human)
Avelos Therapeutics

US Patent
LigandPNGBDBM696121(US20240300936, Example 117)
Affinity DataIC50: 1.95nMAssay Description:Wild-type human MASTL (0.5 nM) was incubated in assay buffer (30 mM HEPES, 100 mM NaCl, 0.5 mM EGTA, 10 mM MgCl2, 0.01% Tween-20, 0.5 mM TCEP, pH 7.5...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetSerine/threonine-protein kinase greatwall(Human)
Avelos Therapeutics

US Patent
LigandPNGBDBM696120(US20240300936, Example 116)
Affinity DataIC50: 2nMAssay Description:Wild-type human MASTL (0.5 nM) was incubated in assay buffer (30 mM HEPES, 100 mM NaCl, 0.5 mM EGTA, 10 mM MgCl2, 0.01% Tween-20, 0.5 mM TCEP, pH 7.5...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetSerine/threonine-protein kinase greatwall(Human)
Avelos Therapeutics

US Patent
LigandPNGBDBM696122(US20240300936, Example 118)
Affinity DataIC50: 2.24nMAssay Description:Wild-type human MASTL (0.5 nM) was incubated in assay buffer (30 mM HEPES, 100 mM NaCl, 0.5 mM EGTA, 10 mM MgCl2, 0.01% Tween-20, 0.5 mM TCEP, pH 7.5...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetSerine/threonine-protein kinase greatwall(Human)
Avelos Therapeutics

US Patent
LigandPNGBDBM696094(US20240300936, Example 85 | N2-[(2-Fluoro-3-methox...)
Affinity DataIC50: 2.29nMAssay Description:Wild-type human MASTL (0.5 nM) was incubated in assay buffer (30 mM HEPES, 100 mM NaCl, 0.5 mM EGTA, 10 mM MgCl2, 0.01% Tween-20, 0.5 mM TCEP, pH 7.5...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetSerine/threonine-protein kinase greatwall(Human)
Avelos Therapeutics

US Patent
LigandPNGBDBM696057(US20240300936, Example 48 | 6-(1H-indazol-6-yl)-N2...)
Affinity DataIC50: 2.40nMAssay Description:Wild-type human MASTL (0.5 nM) was incubated in assay buffer (30 mM HEPES, 100 mM NaCl, 0.5 mM EGTA, 10 mM MgCl2, 0.01% Tween-20, 0.5 mM TCEP, pH 7.5...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetSerine/threonine-protein kinase greatwall(Human)
Avelos Therapeutics

US Patent
LigandPNGBDBM696032(US20240300936, Example 23)
Affinity DataIC50: 2.45nMAssay Description:Wild-type human MASTL (0.5 nM) was incubated in assay buffer (30 mM HEPES, 100 mM NaCl, 0.5 mM EGTA, 10 mM MgCl2, 0.01% Tween-20, 0.5 mM TCEP, pH 7.5...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetSerine/threonine-protein kinase greatwall(Human)
Avelos Therapeutics

US Patent
LigandPNGBDBM696081(US20240300936, Example 72 | 6-imidazo[1,5-a]pyridi...)
Affinity DataIC50: 2.69nMAssay Description:Wild-type human MASTL (0.5 nM) was incubated in assay buffer (30 mM HEPES, 100 mM NaCl, 0.5 mM EGTA, 10 mM MgCl2, 0.01% Tween-20, 0.5 mM TCEP, pH 7.5...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetSerine/threonine-protein kinase greatwall(Human)
Avelos Therapeutics

US Patent
LigandPNGBDBM696093(US20240300936, Example 84 | N4-[1-[4-chloro-1-(dif...)
Affinity DataIC50: 2.82nMAssay Description:Wild-type human MASTL (0.5 nM) was incubated in assay buffer (30 mM HEPES, 100 mM NaCl, 0.5 mM EGTA, 10 mM MgCl2, 0.01% Tween-20, 0.5 mM TCEP, pH 7.5...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetSerine/threonine-protein kinase greatwall(Human)
Avelos Therapeutics

US Patent
LigandPNGBDBM696043(US20240300936, Example 34 | N4-[1-[1-(difluorometh...)
Affinity DataIC50: 2.95nMAssay Description:Wild-type human MASTL (0.5 nM) was incubated in assay buffer (30 mM HEPES, 100 mM NaCl, 0.5 mM EGTA, 10 mM MgCl2, 0.01% Tween-20, 0.5 mM TCEP, pH 7.5...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetSerine/threonine-protein kinase greatwall(Human)
Avelos Therapeutics

US Patent
LigandPNGBDBM696077(US20240300936, Example 68 | US20240300936, Example...)
Affinity DataIC50: 2.95nMAssay Description:Wild-type human MASTL (0.5 nM) was incubated in assay buffer (30 mM HEPES, 100 mM NaCl, 0.5 mM EGTA, 10 mM MgCl2, 0.01% Tween-20, 0.5 mM TCEP, pH 7.5...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetSerine/threonine-protein kinase greatwall(Human)
Avelos Therapeutics

US Patent
LigandPNGBDBM696110(US20240300936, Example 101 | N2-[1-[1-(difluoromet...)
Affinity DataIC50: 2.95nMAssay Description:Wild-type human MASTL (0.5 nM) was incubated in assay buffer (30 mM HEPES, 100 mM NaCl, 0.5 mM EGTA, 10 mM MgCl2, 0.01% Tween-20, 0.5 mM TCEP, pH 7.5...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetSerine/threonine-protein kinase greatwall(Human)
Avelos Therapeutics

US Patent
LigandPNGBDBM696139(US20240300936, Example 137)
Affinity DataIC50: 2.95nMAssay Description:Wild-type human MASTL (0.5 nM) was incubated in assay buffer (30 mM HEPES, 100 mM NaCl, 0.5 mM EGTA, 10 mM MgCl2, 0.01% Tween-20, 0.5 mM TCEP, pH 7.5...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetSerine/threonine-protein kinase greatwall(Human)
Avelos Therapeutics

US Patent
LigandPNGBDBM696034(US20240300936, Example 25)
Affinity DataIC50: 3.02nMAssay Description:Wild-type human MASTL (0.5 nM) was incubated in assay buffer (30 mM HEPES, 100 mM NaCl, 0.5 mM EGTA, 10 mM MgCl2, 0.01% Tween-20, 0.5 mM TCEP, pH 7.5...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetSerine/threonine-protein kinase greatwall(Human)
Avelos Therapeutics

US Patent
LigandPNGBDBM696126(US20240300936, Example 122)
Affinity DataIC50: 3.09nMAssay Description:Wild-type human MASTL (0.5 nM) was incubated in assay buffer (30 mM HEPES, 100 mM NaCl, 0.5 mM EGTA, 10 mM MgCl2, 0.01% Tween-20, 0.5 mM TCEP, pH 7.5...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetSerine/threonine-protein kinase greatwall(Human)
Avelos Therapeutics

US Patent
LigandPNGBDBM696111(US20240300936, Example 102 | N2-[1-[1-(difluoromet...)
Affinity DataIC50: 3.16nMAssay Description:Wild-type human MASTL (0.5 nM) was incubated in assay buffer (30 mM HEPES, 100 mM NaCl, 0.5 mM EGTA, 10 mM MgCl2, 0.01% Tween-20, 0.5 mM TCEP, pH 7.5...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetSerine/threonine-protein kinase greatwall(Human)
Avelos Therapeutics

US Patent
LigandPNGBDBM696044(US20240300936, Example 35 | N4-[1-[1-(Difluorometh...)
Affinity DataIC50: 3.24nMAssay Description:Wild-type human MASTL (0.5 nM) was incubated in assay buffer (30 mM HEPES, 100 mM NaCl, 0.5 mM EGTA, 10 mM MgCl2, 0.01% Tween-20, 0.5 mM TCEP, pH 7.5...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetSerine/threonine-protein kinase greatwall(Human)
Avelos Therapeutics

US Patent
LigandPNGBDBM696137(US20240300936, Example 135)
Affinity DataIC50: 3.72nMAssay Description:Wild-type human MASTL (0.5 nM) was incubated in assay buffer (30 mM HEPES, 100 mM NaCl, 0.5 mM EGTA, 10 mM MgCl2, 0.01% Tween-20, 0.5 mM TCEP, pH 7.5...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetSerine/threonine-protein kinase greatwall(Human)
Avelos Therapeutics

US Patent
LigandPNGBDBM696106(US20240300936, Example 97 | N4-[1-[4-chloro-1-(dif...)
Affinity DataIC50: 3.80nMAssay Description:Wild-type human MASTL (0.5 nM) was incubated in assay buffer (30 mM HEPES, 100 mM NaCl, 0.5 mM EGTA, 10 mM MgCl2, 0.01% Tween-20, 0.5 mM TCEP, pH 7.5...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetSerine/threonine-protein kinase greatwall(Human)
Avelos Therapeutics

US Patent
LigandPNGBDBM696026(US20240300936, Example 17)
Affinity DataIC50: 3.89nMAssay Description:Wild-type human MASTL (0.5 nM) was incubated in assay buffer (30 mM HEPES, 100 mM NaCl, 0.5 mM EGTA, 10 mM MgCl2, 0.01% Tween-20, 0.5 mM TCEP, pH 7.5...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetSerine/threonine-protein kinase greatwall(Human)
Avelos Therapeutics

US Patent
LigandPNGBDBM696083(US20240300936, Example 74 | N2-[[1-(difluoromethyl...)
Affinity DataIC50: 4.07nMAssay Description:Wild-type human MASTL (0.5 nM) was incubated in assay buffer (30 mM HEPES, 100 mM NaCl, 0.5 mM EGTA, 10 mM MgCl2, 0.01% Tween-20, 0.5 mM TCEP, pH 7.5...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetSerine/threonine-protein kinase greatwall(Human)
Avelos Therapeutics

US Patent
LigandPNGBDBM696138(US20240300936, Example 136)
Affinity DataIC50: 4.27nMAssay Description:Wild-type human MASTL (0.5 nM) was incubated in assay buffer (30 mM HEPES, 100 mM NaCl, 0.5 mM EGTA, 10 mM MgCl2, 0.01% Tween-20, 0.5 mM TCEP, pH 7.5...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetSerine/threonine-protein kinase greatwall(Human)
Avelos Therapeutics

US Patent
LigandPNGBDBM696017(US20240300936, Example 8 | 6-(1H-indazol-6-yl)-N2-...)
Affinity DataIC50: 4.57nMAssay Description:Wild-type human MASTL (0.5 nM) was incubated in assay buffer (30 mM HEPES, 100 mM NaCl, 0.5 mM EGTA, 10 mM MgCl2, 0.01% Tween-20, 0.5 mM TCEP, pH 7.5...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetSerine/threonine-protein kinase greatwall(Human)
Avelos Therapeutics

US Patent
LigandPNGBDBM696060(US20240300936, Example 51 | N2-[(6-chloro-2,3-difl...)
Affinity DataIC50: 4.57nMAssay Description:Wild-type human MASTL (0.5 nM) was incubated in assay buffer (30 mM HEPES, 100 mM NaCl, 0.5 mM EGTA, 10 mM MgCl2, 0.01% Tween-20, 0.5 mM TCEP, pH 7.5...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetSerine/threonine-protein kinase greatwall(Human)
Avelos Therapeutics

US Patent
LigandPNGBDBM696073(US20240300936, Example 64 | 6-(1H-indazol-6-yl)-N2...)
Affinity DataIC50: 4.68nMAssay Description:Wild-type human MASTL (0.5 nM) was incubated in assay buffer (30 mM HEPES, 100 mM NaCl, 0.5 mM EGTA, 10 mM MgCl2, 0.01% Tween-20, 0.5 mM TCEP, pH 7.5...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetSerine/threonine-protein kinase greatwall(Human)
Avelos Therapeutics

US Patent
LigandPNGBDBM696015(US20240300936, Example 6 | 6-(1H-indazol-6-yl)-N2-...)
Affinity DataIC50: 4.79nMAssay Description:Wild-type human MASTL (0.5 nM) was incubated in assay buffer (30 mM HEPES, 100 mM NaCl, 0.5 mM EGTA, 10 mM MgCl2, 0.01% Tween-20, 0.5 mM TCEP, pH 7.5...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetSerine/threonine-protein kinase greatwall(Human)
Avelos Therapeutics

US Patent
LigandPNGBDBM696048(US20240300936, Example 39 | N4-[1-(2,3-difluorophe...)
Affinity DataIC50: 4.90nMAssay Description:Wild-type human MASTL (0.5 nM) was incubated in assay buffer (30 mM HEPES, 100 mM NaCl, 0.5 mM EGTA, 10 mM MgCl2, 0.01% Tween-20, 0.5 mM TCEP, pH 7.5...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetSerine/threonine-protein kinase greatwall(Human)
Avelos Therapeutics

US Patent
LigandPNGBDBM696143(US20240300936, Example 141)
Affinity DataIC50: 5.13nMAssay Description:Wild-type human MASTL (0.5 nM) was incubated in assay buffer (30 mM HEPES, 100 mM NaCl, 0.5 mM EGTA, 10 mM MgCl2, 0.01% Tween-20, 0.5 mM TCEP, pH 7.5...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetSerine/threonine-protein kinase greatwall(Human)
Avelos Therapeutics

US Patent
LigandPNGBDBM696010(US20240300936, Example 1 | 6-(1H-indazol-6-yl)-N2-...)
Affinity DataIC50: 5.5nMAssay Description:Wild-type human MASTL (0.5 nM) was incubated in assay buffer (30 mM HEPES, 100 mM NaCl, 0.5 mM EGTA, 10 mM MgCl2, 0.01% Tween-20, 0.5 mM TCEP, pH 7.5...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetSerine/threonine-protein kinase greatwall(Human)
Avelos Therapeutics

US Patent
LigandPNGBDBM696098(US20240300936, Example 89 | N2-(6-fluoro-2,3-dihyd...)
Affinity DataIC50: 5.5nMAssay Description:Wild-type human MASTL (0.5 nM) was incubated in assay buffer (30 mM HEPES, 100 mM NaCl, 0.5 mM EGTA, 10 mM MgCl2, 0.01% Tween-20, 0.5 mM TCEP, pH 7.5...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetSerine/threonine-protein kinase greatwall(Human)
Avelos Therapeutics

US Patent
LigandPNGBDBM696092(US20240300936, Example 83 | 6-(1H-Indazol-6-yl)-N2...)
Affinity DataIC50: 5.89nMAssay Description:Wild-type human MASTL (0.5 nM) was incubated in assay buffer (30 mM HEPES, 100 mM NaCl, 0.5 mM EGTA, 10 mM MgCl2, 0.01% Tween-20, 0.5 mM TCEP, pH 7.5...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetSerine/threonine-protein kinase greatwall(Human)
Avelos Therapeutics

US Patent
LigandPNGBDBM696119(US20240300936, Example 115)
Affinity DataIC50: 5.89nMAssay Description:Wild-type human MASTL (0.5 nM) was incubated in assay buffer (30 mM HEPES, 100 mM NaCl, 0.5 mM EGTA, 10 mM MgCl2, 0.01% Tween-20, 0.5 mM TCEP, pH 7.5...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetSerine/threonine-protein kinase greatwall(Human)
Avelos Therapeutics

US Patent
LigandPNGBDBM696054(US20240300936, Example 45 | N4-[(2,3-Difluoropheny...)
Affinity DataIC50: 6.17nMAssay Description:Wild-type human MASTL (0.5 nM) was incubated in assay buffer (30 mM HEPES, 100 mM NaCl, 0.5 mM EGTA, 10 mM MgCl2, 0.01% Tween-20, 0.5 mM TCEP, pH 7.5...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

Displayed 1 to 50 (of 134 total ) | Next | Last >>
Jump to: